Klaus Diergarten, MD

home / authors / klaus-diergarten-md

Articles

Infusional 5-FU, Folinic Acid, Paclitaxel, and Cisplatin for Metastatic

Ute Klaassen, MD;Hans Jochen Wilke, MD;Christian Müller, MD;David Borquez, MD;Michael Korn, MD;Klaus Diergarten, MD;Siegfried Seeber, MD, PhD

April 1st 1997

Our phase II study results demonstrating high efficacy and low toxicity for a weekly schedule of high-dose, 24-hour infusional 5-fluorouracil(5-FU)/folinic acid (HD5-FU/FA) in intensively pretreated patients with metastatic

Paclitaxel and Epirubicin as First-Line Therapy for Patients With Metastatic Breast Cancer

Hans-Joachim Lück, MD;Andreas Du Bois, MD, PhD;Christoph Thomssen, MD, PhD;Björn Lisboa, MD, PhD;Michael Untch, MD, PhD;Günther Köhler, MD, PhD;Detlev Hecker, PhD;Klaus Diergarten, MD

April 1st 1997

Paclitaxel (Taxol) has aroused considerable interest for its high single-agent activity in breast cancer and novel mechanism of action. Epirubicin (Farmorubicin), the 4'epimer of doxorubicin (Adriamycin), also has high activity in